Bioasis Technologies (BIOAF) Stock Price, News & Analysis

Company Overview

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0130
• Volume: N/A
• Average Volume: 10,957 shs
• Market Capitalization: $31,764.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOAF Stock Analysis - Frequently Asked Questions

How have BIOAF shares performed this year?

Bioasis Technologies' stock was trading at $0.0001 at the start of the year. Since then, BIOAF shares have increased by 300.0% and is now trading at $0.0004.
View the best growth stocks for 2025 here.

How were Bioasis Technologies' earnings last quarter?

Bioasis Technologies Inc. (OTCMKTS:BIOAF) posted its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01).

How do I buy shares of Bioasis Technologies?

Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 10/27/2021
• Today: 5/02/2025
• Fiscal Year End: 2/28/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOAF
• CIK: N/A
• Web: www.bioasis.us
• Phone: (203) 533-7082
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $30,000.00
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 79,410,000
• Free Float: N/A
• Market Cap: $31,764.00
• Optionable: Not Optionable
• Beta: 0.97